Although more experiments and higher doses are still required to better describe pFasL toxicity and activity, it appears that for a future therapeutic use in cancer treatment, the design of soluble FasL forms spontaneously reaching a high degree of polymerization should also consider their ability to trigger the adequate Fas receptor conformational adaptation. The gene discussed is FASLG; the disease is cancer.